Cypherpunk Technologies Inc. CYPH

Nasdaq · Phase 2 · oncology · antibody · EDGAR · Updated Oct 24, 2026

Cypherpunk Technologies Inc. (Nasdaq: CYPH) is an oncology life-science company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
Sirexatamab (DKN-01)	DKK1-high second-line metastatic colorectal cancer (randomized Phase 2 DeFianCe completed; Phase 3 design agreed with FDA, not started)	antibody	Phase 2
FL-501	Cachexia-related indications	antibody	Pre-clinical

Aug 12, 2026
missed Peer-reviewed DeFianCe Phase 2 publication: primary endpoint (PFS) not met in the ITT population; benefit increased with higher baseline plasma DKK1 (exploratory).while the prespecified primary endpoint was not met in the intent-to-treat population, the benefit of sirexatamab increases as a patient's baseline plasma DKK1 level rises Filing
Aug 12, 2026
n/a Following a Type C meeting, Leap reached FDA alignment on a ~270-patient randomized Phase 3 (ORR for accelerated approval in ~160 patients, OS for full approval).Leap Therapeutics reached alignment with the FDA on a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with investigator’s-choice fluoropyrimidine-based chemotherapy (FOLFIRI or mFOLFOX6) plus bevacizumab, compared with chemotherapy and bevacizumab alone. Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export